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Background: Reducing nebulisation times for tobramycin solution for inhalation in cystic fibrosis (CF) may improve compliance.
Methods: In this single-dose, open-label, two-way crossover study, 13 subjects (7 CF, 6 healthy) were randomised to receive tobramycin via
eFlow rapid or LC Plus jet nebuliser. Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacokinetics, and
safety were evaluated.
Results: In CF patients, whole-lung deposition was 40% less with the eFlow rapid compared with LC Plus nebulisers was (8.9±0.8%, and
15.1±6.0%, pN0.05). Nebulisation time was shorter with eFlow rapid compared to LC Plus (7.0 min versus 20.0 min, pb0.05). Lung deposition
in healthy subjects was comparable between both devices.
Conclusions: eFlow rapid reduces the nebulisation time of tobramycin and can potentially improved compliance in patients with CF.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Nebuliser; Tobramycin; Aerosol; Pharmacokinetics; Pharmacoscintigraphy1. Introduction
Patients with cystic fibrosis (CF) often become chronically
infected with Pseudomonas aeruginosa. This chronic infection is
associated with acute exacerbations and progressive lung damage
necessitating treatment with parenteral antibiotics [1]. The
standard therapy for P. aeruginosa respiratory infections is
parenteral antipseudomonal antibiotics, which penetrate poorly
into the endobronchial space [2]. Therefore, inhalation of
aerosolised antibiotics enables delivery of high concentrations
directly to the lungs with minimal systemic absorption and
toxicity [3,4]. The most commonly used aerosolised antibiotics
are tobramycin and colistimethate sodium,which can be delivered
twice daily for prolonged periods of time [3]. A preservative-free⁎ Corresponding author. Tel.: +44 1403 324658; fax: +44 1403 323060.
E-mail address: pearl.kho@novartis.com (P. Kho).
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.08.019and stable formulation of tobramycin solution (TOBI®, 300 mg in
5 mL of 1/4 normal saline) is available for the long-term
management of P. aeruginosa infection in patients with CF
[5,6]. It has been studied extensively [7] and is recommended to
be administered using the LC Plus jet nebuliser (PARI GmbH,
Stranberg, Germany) powered by a suitable compressor, which
delivers a flow rate of 4–6 L/min and/or a back pressure of 110–
217 kPa.
Administration with this nebuliser takes approximately
15–20 min [8]. Patient compliance and acceptance of a twice-
daily tobramycin regimen may be improved by decreasing the
nebulisation time using an alternative drug delivery system [9]. A
wide range of commercially available nebulisers have been tested
as alternatives to administration of tobramycin [10,11]. The
battery-driven eFlow rapid nebuliser (PARI Respiratory Equip-
ment Inc., Midlothian, VA, USA) is designed to deliver liquid or
suspension formulations for inhalation more rapidly than the jet
nebulisers [8,12].d by Elsevier B.V. All rights reserved.
Fig. 1. Activity distribution of radiolabelled tobramycin in lung regions. Six
lung-shaped regions: regions 1–4=mainly large conducting airways; regions 5
and 6=mainly small airways and alveoli. Adapted from Newman et al. [13].
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the in vivo lung deposition of 300 mg tobramycin inhaled using
the PARI eFlow rapid electronic nebuliser (with no compres-
sor) in comparison with the deposition of 300 mg tobramycin
inhaled using the PARI LC Plus jet nebuliser (with an
appropriate compressor). Nebulisation times, safety, drug
deposition, and pharmacokinetic (PK) parameters of tobramy-
cin were also assessed.
2. Methods
2.1. Study design
This was a phase I, multi-centre, randomised, single-dose,
open-label, crossover study of tobramycin (TOBI®, 300 mg in
5 mL of 1/4 normal saline) in healthy volunteers and CF patients.
The protocol was approved by the ethics committee of each study
centre (University Hospital of North Staffordshire, Northern
General Hospital, Sheffield and Pharmaceutical Profiles Ltd.,
Nottingham). Written informed consent was obtained from all
subjects.
2.2. Study population
2.2.1. Inclusion criteria
Healthy male and female volunteers aged between 18 and
65 years, within ±25% of their ideal weight (using the Body
Mass Index [BMI] method) and with an initial percent predicted
forced expiratory volume at 1 s (%FEV1)≥80% were included.
In addition, male and female CF patients aged 18–65 years with
chronic P. aeruginosa infection and a screening % predicted
FEV1≥25% were invited to take part. The use of any
investigational treatment or new medication within 1 month
prior to screening and throughout the study was prohibited.
Previous use of tobramycin and other regular medicines was
documented. A 1-week washout period for all subjects
receiving tobramycin or other aminoglycoside antibiotics or a
2-day washout period for those receiving colistimethate sodium
was required prior to enrolment.
2.2.2. Exclusion criteria
Subjects were excluded if they had a history of smoking or
alcoholism, had a known hypersensitivity to aminoglycosides
or salbutamol, or had received administration of a loop diuretic
within 7 days prior to screening. Subjects with impaired renal
function or other clinically significant abnormal biochemistry,
haematology, or urinalysis values were also excluded.
2.3. Study duration and treatment assignment
The study duration was approximately 6 weeks: a 4-week
screening period and two treatment periods with follow-up within
14 days of the last dose. A single dose of aerosolised tobramycin
radiolabelled with sterile technetium bound to diethylene triamine
penta acetic acid (99mTc DTPA) was delivered via either the
eFlow rapid nebuliser (experimental treatment A) or the LC Plus
nebuliser (control treatment B). Stop times of nebulisation aredefined as the time when the nebuliser becomes dry and
automatically stops (eFlow rapid nebuliser) or when the nebuliser
begins to sputter and nebulisation is stopped manually (LC Plus
nebuliser). All subjects were randomly assigned (1:1) to receive
treatments in the order AB or BA. The doses were administered
on the morning of Day 1 of each of the two treatment periods,
which were separated by a minimum washout period of 72 h. All
subjects were pre-treated with 200 μg of inhaled salbutamol 15–
60 min before tobramycin administration, but after the pre-dose
spirometry test. If bronchoconstriction occurred after inhalation of
tobramycin, the salbutamol was administered as required.
2.4. Aerosol delivery assessments
Deposition patterns of inhaled radiolabelled tobramycin were
determined using two-dimensional gamma scintigraphic imaging
methodology [13]. Lung, oropharyngeal, and abdominal radio-
activity were measured from images obtained immediately after
the completion of each tobramycin dose using a gamma camera
(General ElectricMaxicamera, GEMedical Systems,Milwaukee,
WI, USA). Each subject underwent transmission scans of the head
and thorax using a flood field source containing 57-Cobalt (57Co)
to correct for attenuation of gamma rays by overlying tissues. The
lung scan outlines were used to divide the lung images of each
subject into six concentric lung-shaped regions radiating from the
hilum (Fig. 1; zones 1–6) to determine the amount of aerosolised
tobramycin deposited in each zone [14,15]. All images were
recorded using Micas X-Plus software (Bartec Technologies,
Camberley, Surrey, UK) installed on a UNIX-based computer
system and were stored for subsequent analysis and archiving.
The scintigraphic data obtained were corrected for back-
ground radioactivity, radioactive decay, and tissue attenuation
[15]. The manipulation and calculation of radioactivity counts
were achieved with the validated custom-written software. The
primary aerosol delivery parameter of interest was the whole-
Table 1
Demographic summary by treatment group (ITT population).
Healthy volunteers
(N=6)
CF patients
(N=7)
eFlow/
LC
LC/
eFlow
eFlow/
LC
LC/
eFlow
Age (in years) 33.3 (9.5) 44.3 (11.2) 21.8 (4.3) 21.3 (3.1)
Male, n (%) a 3 (100) 3 (100) 2 (50) 2 (67)
Female, n (%) a 0 0 2 (50) 1 (33)
Mean BMI 24.6 27.2 20.4 20.5
Inhaled tobramycin
prior to study
0 0 0 2
Inhaled other aminoglycosides
prior to study
0 0 1 1
Mean pre-dose FEV1%
predicted at period 1
99.2 93.2 65.5 53.3
Values for age, weight, and height are mean (standard deviation).
BMI, body mass index.
a Since this was a crossover study, a patient randomised to inhale tobramycin
with eFlow rapid in the first periodwill also receive tobramycinwith LCPlus in the
second period, and vice versa. Therefore a total of 6 male healthy volunteers and 7
CF patients received tobramycin with both LC Plus and eFlow rapid.
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mg). The deposition counts in each area were expressed as a
percentage of the metered dose determined from the sum of the
total body radioactivity counts plus the inhaler and exhalation
filter deposition counts. To facilitate interpretation of the data,
the amounts of drug deposited in milligrams for each of the
deposition parameters were estimated.
Whole-lung deposition was evaluated descriptively for
differences between the aerosol delivery systems and between
the subject groups. Additional aerosol delivery measures of
interest were deposition in lung zones 1–6, oropharynx
(including oesophagus and stomach), nebulisers, and exhalation
filters (level of radio aerosol in exhaled air) [14].
Nebulisation times and dose interruptions were also recorded.
2.5. Pharmacokinetic assessments
Venous blood samples were collected pre-dose and at 0.5, 1,
2, 4 and 8 h post-inhalation of tobramycin. Serum was
harvested and frozen at less than −70 °C until analysis. Con-
centrations of tobramycin in serum were analysed with a
modified fluorescence polarisation immunoassay [16] using the
Abbott TDx/TDxFLx system (Abbott Laboratories, Abbott
Park, IL, USA). PK parameters included area under the curve
from time 0 to 8 h (AUC0–8, [μg h/mL]), peak concentration
(Cmax, μg/mL), time to reach maximum concentration (tmax),
and half-life (t1/2). The occurrence of high serum tobramycin
concentrations that may be associated with toxicity was
assessed. The thresholds were pre-defined in the protocol as
trough concentrations N2 μg/mL, Cmax N12 μg/mL, and con-
centrations at any other time post-dose N4 μg/mL [17].
2.6. Safety assessments
2.6.1. Analysis of bronchospasm
Changes in pulmonary function were used to assess airway
reactivity after the drug inhalations. Reductions in %FEV1 by b
20% were deemed clinically insignificant, those≥20% but b30%
were considered to be clinically significant and those ≥30% were
considered to indicate severe bronchospasm.
2.6.2. Adverse events
All adverse events (AEs) were recorded, including the
potential for increased risk of systemic toxicity as determined
by serum concentrations of tobramycin.
2.7. Statistical analyses
All subjects who received at least one dose of medication
were included in the intention-to-treat population and were
evaluable for safety and aerosol delivery characteristics. Only
those who participated in both arms of the trial and provided
appropriate samples and measurements were included in the
deposition-evaluable and pharmacokinetics-evaluable popula-
tions. The aim of this exploratory study was to look for trends in
nebulisation time and PK parameters produced by the two
nebulisers in a representative number of patients; hence, therewas no formal statistical basis for the size of the patient
population, and descriptive statistics were initially planned to
summarise the data. Subsequently, a post-hoc random-effect
analysis of variance to assess the devices' effects on nebulisa-
tion time and PK parameters was performed. The coefficient of
determination (r2) was used to assess relationships between the
deposition of tobramycin in the lungs and tobramycin PK
parameters in serum. r2 gives the proportion of the variance in
serum PK parameters explained by drug deposition in the lung.
All clinical data management, transformation, and analyses
were performed using SAS version 9.1 (SAS Institute Inc.,
Cary, NC, USA).
3. Results
3.1. Patient demographics and baseline characteristics
Thirteen subjects (six healthy volunteers and seven CF patients)
were enrolled. One CF patient withdrew consent and did not
complete the study. The deposition- and pharmacokinetics-
evaluable populations consisted of all six healthy volunteers and
the six CF patients who completed the study. The mean BMI for
healthy subjects was 26 and that for the CF patients was 20.5. The
FEV1 prior to any dose administration for each treatment group is
shown in Table 1. None of the healthy volunteers had a history of
respiratory disorder or previous treatment with tobramycin or other
inhaled aminoglycosides, whereas 29% (n=2) of the CF patients
had previously used tobramycin (Table 1).
3.2. Aerosol delivery
Whole-lung deposition of tobramycin (in terms of median
percentage of metered dose) was similar with the eFlow rapid
and LC Plus in healthy volunteers (13.3±6.5% and 14.8±1.8%,
Table 2). In CF patients, whole-lung deposition was approxi-
mately 40% less with the eFlow rapid compared to the LC Plus
Table 2
Distribution of tobramycin activity in the whole-lung, oropharynx, devices, and
exhaled air (deposition-evaluable patients).
LC Plus eFlow rapid
Healthy (N=6) CF (N=6) Healthy (N=6) CF (N=6)
Median% metered dose (SD)
Whole-lung 14.8 (1.8) 15.1 (6.0) 13.3 (6.5) 8.9 (0.8)
Oropharynx a 8.5 (1.8) 7.5 (5.8) 4.4 (3.5) 5.1 (3.4)
Device 58.6 (13.5) 57.5 (25.5) 52.2 (10.1) 65.2 (11.1)
Exhaled air b 20.5 (12.2) 20.5 (15.8) 25.0 (11.3) 24.5 (8.7)
Drug deposited (mg)
Whole-lung 44.3 (5.5) 45.2 (18.1) 40.0 (19.5) 26.6 (2.5)
Oropharynx a 25.4 (5.5) 22.4 (17.5) 13.1 (10.5) 15.2 (10.1)
Device 175.8 (40.4) 172.5 (76.5) 156.5 (30.2) 195.6 (33.3)
Exhaled air b 61.4 (36.5) 70.1 (43.3) 74.8 (33.8) 73.5 (26.0)
Drug deposition values are expressed as median (standard deviation).
CF, cystic fibrosis.
a Sum of esophagus, oropharynx and stomach.
b Sum of exhalation filter, mouthpiece, T-piece, scavenger filter, and tissues.
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ence was not statistically significant (pN0.05, n=6). The amount
of tobramycin remaining in either device was similar in healthy
subjects. Oropharyngeal deposition was low for both nebulisers
(b10% of the total) and in both populations (Table 2).
Tobramycin distribution across the different zones of lung
was similar between the nebulisers for both CF patients and
healthy volunteers (Table 3). The highest deposition within the
lungs occurred in the most central lung region (lung region 1)Table 3
Distribution of tobramycin activity between the different zones of the lungs
(deposition-evaluable population).
Lung
Zones
LC Plus eFlow rapid
Healthy (N=6) CF (N=6) Healthy (N=6) CF (N=6)
% Metered dose
1 3.8 (0.5) 3.9 (1.3) 2.9 (1.5) 2.6 (0.5)
2 1.6 (0.2) 1.6 (0.6) 1.2 (0.7) 1.0 (0.1)
3 2.1 (0.3) 2.1 (0.7) 1.8 (0.8) 1.3 (0.2)
4 2.7 (0.4) 2.8 (1.0) 2.3 (1.2) 1.6 (0.3)
5 2.7 (0.4) 3.0 (1.5) 2.8 (1.2) 1.6 (0.4)
6 1.5 (0.5) 1.8 (1.1) 2.3 (1.1) 1.1(0.3)
Drug deposited (mg)
1 11.3 (1.6) 11.6 (4.0) 8.8 (4.5) 7.7 (1.4)
2 4.9 (0.7) 4.7 (1.7) 3.7 (2.1) 2.9 (0.3)
3 6.3 (0.9) 6.3 (2.1) 5.4 (2.5) 3.9 (0.5)
4 8.0 (1.1) 8.4 (3.1) 7.0 (3.5) 4.7 (1.0)
5 7.9 (1.3) 8.9 (4.4) 8.1 (3.6) 4.7 (1.1)
6 4.5 (1.4) 5.4 (3.3) 6.9 (3.4) 3.3 (0.9)
Airway penetration factors
1 1.3 (0.1) 1.2 (0.1) 1.2 (0.1) 1.4 (0.4)
2 1.3 (0.1) 1.2 (0.04) 1.2 (0.1) 1.3 (0.03)
3 1.2 (0.1) 1.2 (0.1) 1.2 (0.03) 1.2 (0.1)
4 1.1 (0.1) 1.1 (0.02) 1.1 (0.1) 1.1 (0.1)
5 0.8 (0.1) 0.8 (0.1) 0.9 (0.03) 0.7 (0.1)
6 0.3 (0.1) 0.4 (0.1) 0.5 (0.1) 0.3 (0.1)
Values are expressed as median (standard deviation).
CF, cystic fibrosis.for both the devices and for both groups of subjects. An
illustration of the various zones can be found in Fig. 1. In order
to quantify the regional lung deposition, the Airway Penetration
Factor (APF) was estimated. APF is defined as the activity
concentration (radioactivity counts per unit area) for a region
divided by the average activity concentration for all six regions
[15]. The mean APF were reasonably similar in regions 1–4
(greater than 1.0, with region 1 being the most central) for both
groups of subjects and with both devices. This suggests that the
central zone as depicted in Fig. 1 has greater than average
activity concentration. In contrast, in the most peripheral lung
regions, that is regions 5 and 6, the mean APFs were b1.0
(Table 3).
For the healthy volunteers, dosing was interrupted in three
subjects with eFlow rapid but not with LC Plus. Dosing was
interrupted in 43% (n=3) of CF patients when using eFlow rapid
and in 33% (n=2) when using the LC Plus device. Interruptions
among CF patients were mainly due to coughing. All subjects
were able to complete the nebulisation procedure. The nebulisa-
tion and dosing times (which included the time when dose was
interrupted) were reduced with eFlow rapid in all subjects. The
median nebulisation times for eFlow rapid compared with LC
Plus were 7.5 versus 16.0 min (pb0.01) in healthy volunteers and
7.0 versus 20.0 min (pb0.05) in CF patients. The median dosing
times for eFlow rapid versus LC Plus nebuliser were 8.5 versus
16.0 min for healthy volunteers and 8.0 versus 20.0 min for CF
subjects. Relative difference between recorded nebulisation time
and dosing time was greater with eFlow rapid than with LC Plus
in both groups due to dosing interruptions (12–13% with eFlow
rapid, 0–1% with LC Plus).
3.3. Pharmacokinetics
The pre-defined drug concentration thresholds that may be
associated with systemic toxicity were not exceeded by any
subject or patient using either of the nebulisers. The mean
tobramycin Cmax ranged from 0.6 to 1.2 μg/mL and occurred
between 0.5 and 2 h after nebulisation (Table 4). In healthy
subjects, tobramycin AUC0–8 was similar with both nebulisers
(3.3±0.7 and 3.6±1.9 μg h/mL for LC Plus and eFlow rapid,
respectively [p=0.96]), whereas in CF patients, it was lower for
eFlow rapid (1.9±0.8 μg h/mL) as compared with LC Plus (5.0±
3.0 μg h/mL; pb0.01). Cmax was also lower for eFlow rapidTable 4
Tobramycin pharmacokinetics (pharmacokinetics-evaluable population).
Parameter Healthy subjects CF patients
LC Plus eFlow rapid LC Plus eFlow rapid
tmax (h) 1 (1–2) 1 (1–2) 1 (0.5–2) 1 (0.5–1)
Cmax (μg/mL) 0.6±0.2 0.7±0.4 1.2±0.6 0.5±0.2
AUC0–8 (μg h/mL) 3.3±0.7 3.6±1.9 5.0±3.0 1.9±0.8
t1/2 (h) 5.8±2.0 4.6±1.2 2.7±1.1 2.7±0.7
Values are arithmetic mean±standard deviation except for tmax which is median
(range).
tmax, time to reach maximum concentration; Cmax, peak serum drug
concentration; AUC 0–8, area under the curve from time 0 to 8 h; t1/2, half-life
and CF, cystic fibrosis.
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values were independent of the type of nebuliser used in CF
patients and healthy volunteers, although t1/2 values were longer
in the healthy subjects. Based on r2, the percentage drug
deposition in the lungs was predictive of the systemic peak
drug exposure using eFlow rapid (r2=0.85) but not for LC Plus
(r2=0.19) in healthy volunteers. In CF patients, lung deposition
was highly predictive of peak drug exposure for LC Plus
(r2=0.92) but not for eFlow rapid (r2=0.39). In both groups, the
stronger correlation was observed for the nebuliser that yielded
the wider range of Cmax values. Hence, the weaker correlations
may have resulted from too narrow an exposure range to robustly
assess the association between deposition of drug in the lung with
systemic drug exposure.
3.4. Safety
AEs were observed in both healthy volunteers and CF
patients with both nebulisers. Most of the AEs were mild and
transient and gave no indication of target organ toxicity.
Respiratory disorders were the most commonly reported AEs.
The frequency of AEs was higher among CF patients (n=3)
than healthy volunteers (n=1) while using LC Plus. One CF
patient during the treatment period with LC Plus was
hospitalised due to fluctuation in blood glucose and weight
loss. With eFlow rapid nebuliser, the incidence rates of AEs
were similar in both treatment groups. One healthy volunteer
experienced skin rash with eFlow rapid, which was suspected to
be study drug related. The most common respiratory tract AE
reported by CF patients was cough (eFlow rapid [n=3] and LC
Plus [n=1]). In CF group, one patient experienced a N10%
reduction in FEV1 after using both inhalers. No patient
experienced clinically significant bronchospasm (decrease in
FEV1 of N20%).
4. Discussion
The clinical effect of aerosolised drugs depends on the dose
reaching the site of action. The administration of aerosolised
antibiotics is most often given using breath-enhanced nebuliser
systems such as LC Plus [12]. The LC Plus nebuliser is the
approved device for administering tobramycin in CF patients with
chronic endobronchial infections caused by P. aeruginosa [18].
Ramsey et al. [19] reported that in combination with an
appropriate compressor it increased the aerosol delivery of
tobramycin, a finding corroborated by others [20,21]. The LC
Plus is superior to many other jet nebulisers with respect to the
time required for nebulisation [22], but the delivery of tobramycin
(300 mg) takes more than 15 min, imposing a significant burden
on CF patients [9]. Improvements in aerosol delivery systems
have allowed shorter nebulisation times, which may improve
patient compliance and quality of life [23]. Although this study
was conducted in a small patient population, it provides initial
evidence that the PARI eFlow rapid nebuliser has a shorter
nebulisation time.
In the present study, whole-lung deposition of tobramycin in
this study was similar with both devices in healthy volunteers,but was approximately 40% lower in CF patients using the
eFlow rapid. More tobramycin also remained in the eFlow
rapid device after it was used by the CF patients. This could be
the result of shallow breathing that may occur in CF patients,
leaving more time for small droplets to coalesce and be
deposited on the device surface. Another factor is that, unlike
the LC Plus, there is no compressor attached to the eFlow rapid
device. The variability seen between the eFlow rapid and the
LC Plus in CF patients may be attributed to the difference in
handling of the nebulisers between healthy subjects and CF
patients, especially with a system that delivers the drug over a
shorter nebulisation time. Patients should therefore be coached
to handle the nebulisers correctly, inhale deeply and slowly
[24]. The wide variability in lung deposition patterns with
eFlow rapid did not allow firm conclusions to be drawn with
respect to this device. In addition, the distribution of different
degrees of lung function in CF patients and its influence on drug
deposition patterns need to be evaluated in larger patient
populations for better understanding of this aspect.
In vitro laboratory data using simulated breathing patterns to
deliver tobramycin [25,26] showed that the eFlow rapid produced
amassmedian aerodynamic diameter (MMAD) about 10%higher
than the LC Plus (mean±SD=3.95±0.07 μm versus 3.54±
0.06 μm) and a narrower particle size distribution pattern than
the LC Plus nebuliser (geometric standard deviation [GSD]±
SD=1.47±0.02 μm versus 2.10±0.01 μm). The influence of
99mTc DTPa on the particle size distribution of tobramycin
aerosol has not been estimated in this study. This is an
acknowledged limitation of the present study. The amount of
99mTc added to tobramycin was not more than 20 MBq 99mTc
DTPA. Coates et al. [27] have shown that the radiolabel and the
drug track together and the values for MMAD and GSD obtained
in this paper are similar to the values reported in this study. In
addition to this study, it has been assumed that Tc nebulisation
parallels tobramycin nebulisation. During nebulisation, it is
possible that the concentration of the nebulised solution may
increase due to preferential nebulisation of the smaller molecules.
The tobramycin concentration in the remaining solution in the
nebuliser could be usually higher by the end of nebulisation. The
previous factors could have an influence on the study results and
need further investigation.
The small patient population and large interpatient variability
in the scintigraphic measurements preclude conclusions on
potential differences in lung deposition between the two devices.
For both devices, tobramycin was deposited across all regions
with higher than average deposition in the central areas than in the
peripheral regions. This observational study was conducted in a
small number of CF patients with screening %predicted
FEV1≥25%. No power calculations were performed to assess
the impact of lung function of drug deposition in lungs. Further
studies on larger patient populations will help to assess this
parameter in CF patients.
The pre-specified threshold serum concentrations, which
might predispose patients to systemic toxicity, were not exceeded
in any subject using either nebuliser. Cmax of tobramycin and
AUC0–8 were in the range of exposures seen in previous PK
studies with these two nebulisers [28]. In healthy subjects,
14 W. Lenney et al. / Journal of Cystic Fibrosis 10 (2011) 9–14systemic tobramycin exposure was comparable between the two
nebulisers. In CF patients, it was lower with the eFlow rapid,
possibly reflecting the relatively lower whole-lung deposition.
Currently, there is no consensus on toxic serum tobramycin levels
when the drug is administered by inhalation. In our protocol, we
used the criteria often applied to intravenous tobramycin
administration given three times daily [29], although whether
these criteria are appropriate to tobramycin by inhalation is not
currently known. Irrespective of this, the highest serum
tobramycin concentration measured in the current study in any
subject or patient at any time point was 1.9 μg/mL.
We have shown in this exploratory study that the eFlow
rapid nebuliser reduced the dosing times although with less
tobramycin deposited in the whole-lung in CF patients
compared with the LC Plus device. It is probable that deposition
is less with eFlow rapid in CF patients. However, this study was
under powered due to its smaller patient population. Hence,
additional studies with larger number of patients are needed to
evaluate the performance and clinical benefit, in terms of
efficacy, of eFlow rapid compared to the currently approved LC
plus device.
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